Opinion on Pharmaceuticals in South and Central America

Published within

« | ... | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | ... | » »|

Type Product title / description Pub Price
Expert View
Expert View

Cytotoxic therapies to feel sting of generics

Cytotoxic therapy has been the cornerstone of cancer treatment for many years: indeed, despite a number of unpleasant side effects, the therapy is relatively effective. However, because of this maturity in the market, generics companies remain keen to emulate the success of several cytotoxic brands that have attained blockbuster sales over the years.

Published By Datamonitor
28 Nov 2008
Expert View
Expert View

DDW 2009: Clostridium difficile-associated colitis

A disease that is gaining more importance both in terms of incidence rates and virulence is Clostridium-difficile-associated colitis. Recurrence rates remain high and an emerging strain has proven to be responsible for an increasing number of outbreaks. At Digestive Disease Week 2009, two companies presented promising updates of their respective programs, both with very different approaches.

Published By Datamonitor
15 Jun 2009
Expert View
Expert View

DDW 2009: the anti-TNF battle

Datamonitor attended this year's Digestive Disease Week (DDW) in Chicago, the world's largest gathering of physicians, researchers and opinion leaders in the field of digestive diseases. An ongoing theme of debate at DDW was the timing of biologic therapy introduction in inflammatory bowel diseases, and the efficacy of combination therapy with TNF inhibitors.

Published By Datamonitor
15 Jun 2009
Expert View
Expert View

Depression sufferers still reluctant to see physician

While the number of individuals with major depressive disorder (MDD) is set to grow only minimally in next two decades, the condition still represents a key health risk, for both society and the individual. For example, MDD is a leading cause of disability and under-diagnosis remains a problem. Furthermore, the leading classes of MDD drugs have been linked to increased suicidality.

Published By Datamonitor
07 Jun 2006
Expert View
Expert View

Directed molecular evolution: lifecycle management for biologics

Although biologics have an extremely attractive growth rate profile compared to small molecules, the rapid market expansion expected to occur between 2005 and 2010 will not continue at the same rate, due in part to the emergence of biosimilars. Thus, biologics manufacturers need to look at optimizing the lifecycle of their products through directed molecular evolution.

Published By Datamonitor
02 Aug 2006
Expert View
Expert View

Diverse challenges await generics industry

Because of the ever-increasing costs of healthcare provision the world over, many governments are enacting legislation to promote generic prescription in order to keep costs down. With drugs worth $160 billion in sales coming off patent by 2015, it would seem a good time to be in the generics industry. However the generics market is not without challenges.

Published By Datamonitor
07 Jul 2006
Expert View
Expert View

Drug reps must embrace technology to avoid missing sales opportunities

In a pharmaceutical market where the days of the primary care blockbuster-selling drug appear numbered, the days of pharma sales representatives having time to visit physicians with drug samples are also waning. Reps must now embrace internet technology to ensure samples are efficiently distributed to physicians and also take on the role of educators in their dynamic relationships with physicians.

Published By Datamonitor
15 Mar 2006
Expert View
Expert View

EASD 2009: Lantus defended amid allegations of increased cancer risk

Datamonitor attended this year's European Association for the Study of Diabetes meeting in Vienna, Austria. Following the issuance of guidance on a potential link between Lantus and increased cancer rates in June 2009, presenters at the conference discussed the current evidence and its limitations. However, a potential mechanism by which insulin could promote cancer cell growth was also proposed.

Published By Datamonitor
14 Oct 2009
Expert View
Expert View

EASD 2009: mixed data as the development pipeline matures

Positive clinical data for dapagliflozin, presented at the European Association for the Study of Diabetes 2009 meeting, have gone some way to allaying physician's fears over the drug's mechanism of action, although concerns over long-term effects remain. Study data were also presented for various GLP-1 agonists, but the results were ultimately inconclusive.

Published By Datamonitor
14 Oct 2009
Expert View
Expert View

EASD 2009: post-marketing data disappoints

Datamonitor attended this year's meeting of the European Association for the Study of Diabetes to assess the key issues currently facing players in this lucrative market. At the conference, Eli Lilly failed to adequately address the potential link between Byetta and pancreatitis, while new data for Galvus and Eucreas may lead to further marginalization for the two drugs.

Published By Datamonitor
14 Oct 2009

« | ... | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | ... | » »|

No help is available.